Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells

Clinical and Experimental Immunology

Volumn 147, Issue 3, 2007, Pages 540-546

  Sugiyama, K ^a   Shirai, R ^a   Mukae, H ^a   Ishimoto, H ^a   Nagata, T ^a   Sakamoto, N ^a   Ishii, H ^a   Nakayama, S ^a   Yanagihara, K ^a   Mizuta, Y ^a   Kohno, S ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Bone marrow derived dendritic cells; Co stimulatory molecules; Cytokines; Macrolides

Indexed keywords

ANTIINFLAMMATORY AGENT; AZITHROMYCIN; B7 ANTIGEN; BIOLOGICAL MARKER; CD40 ANTIGEN; CD86 ANTIGEN; CLARITHROMYCIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 2; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROLIDE; MIDECAMYCIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; CELL CULTURE; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; T LYMPHOCYTE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIGENS, CD; AZITHROMYCIN; BONE MARROW CELLS; CELLS, CULTURED; CLARITHROMYCIN; COCULTURE TECHNIQUES; CYTOKINES; DENDRITIC CELLS; FEMALE; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES;

EID: 33846837316     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03299.x     Document Type: Article

References (44)

1. Kudoh S, Azuma A, Yamamoto M et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998; 157:1829-32.
2. Kadota J, Mukae H, Ishii H et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med 2003; 97:844-50.
3. Kobayashi H, Takeda H, Sakayori S et al. [Study on azithromycin in treatment of diffuse panbronchiolitis]. Kansenshogaku Zasshi 1995; 69:711-22.
4. Wolter J, Seeney S, Bell S et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57:212-6.
5. Equi A, Balfour-Lynn IM, Bush A et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002; 360:978-84.
6. Sakata K, Yajima H, Tanaka K et al. Erythromycin inhibits the production of elastase by Pseudomonas aeruginosa without affecting its proliferation in vitro. Am Rev Respir Dis 1993; 148:1061-5.
7. Yanagihara K, Kadoto J, Kohno S. Diffuse panbronchiolitis - pathophysiology and treatment mechanisms. Int J Antimicrob Agents 2001; 18 (Suppl. 1):S83-7.
8. Kadota J, Sakito O, Kohno S et al. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993; 147:153-9.
9. Mukae H, Kadota J, Kohno S et al. Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis. Am J Respir Crit Care Med 1995; 152:613-18.
10. Morikawa K, Zhang J, Nonaka M et al. Modulatory effect of macrolide antibiotics on the Th1- and Th2-type cytokine production. Int J Antimicrob Agents 2002; 19:53-9.
11. Khan AA, Slifer TR, Araujo FG et al. Effect of clarithromycin and azithromycin on production of cytokines by humanmonocytes. Int J Antimicrob Agents 1999; 11:121-32.
12. Morikawa K, Watabe H, Araake M et al. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob Agents Chemother 1996; 40:1366-70.
13. Sakito O, Kadota J, Kohno S et al. Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996; 63:42-8.
14. Mukae H, Kadota J, Ashitani J et al. Elevated levels of soluble adhesion molecules in serum of patients with diffuse panbronchiolitis. Chest 1997; 112:1615-21.
15. Takizawa H, Desaki M, Ohtoshi T et al. Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells: a potential mechanism of its anti-inflammatory action. Biochem Biophys Res Commun 1995; 210:781-6.
16. Nagata T, Mukae H, Kadota J et al. Effect of erythromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model. Antimicrob Agents Chemother 2004; 48:2251-9.
17. Tateda K, Comte R, Pechere JC et al. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001; 45:1930-3.
18. Lambrecht BN, Prins JB, Hoogsteden HC. Lung dendritic cells and host immunity to infection. Eur Respir J 2001; 18:692-704.
19. Todate A, Chida K, Suda T et al. Increased numbers of dendritic cells in the bronchiolar tissues of diffuse panbronchiolitis. Am J Respir Crit Care Med 2000; 162:148-53.
20. Yasutomi M, Ohshima Y, Omata N et al. Erythromycin differentially inhibits lipopolysaccharide- or poly(I:C)-induced but not peptidoglycan-induced activation of human monocyte-derived dendritic cells. J Immunol 2005; 175:8069-76.
21. Nagata T, Mukai H, Kadokawa T et al. [Two cases successfully treated with long-term administration of low-dosage azithromycin]. Jpn J Antibiot 2001; 54 (Suppl. C):5-8.
22. Lutz MB, Kukutsch N, Ogilvie AL et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Meth 1999; 223:77-92.
23. Morris DL, De Souza A, Jones JA et al. High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose. Eur J Clin Microbiol Infect Dis 1991; 10:859-61.
24. McCarty JM. Clarithromycin in the management of community-acquired pneumonia. Clin Ther 2000; 22:281-94;discussion 65.
25. Wang S, Chen L. Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. Microbes Infect 2004; 6:759-66.
26. Harris NL, Ronchese F. The role of B7 co-stimulation in T-cell immunity. Immunol Cell Biol 1999; 77:304-11.
27. Kuchroo VK, Das MP, Brown JA et al. B7-1 and B7-2 co-stimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995; 80:707-18.
28. Schweitzer AN, Borriello F, Wong RC et al. Role of co-stimulators in T cell differentiation: studies using antigen-presenting cells lacking expression of CD80 or CD86. J Immunol 1997; 158:2713-22.
29. Joss A, Akdis M, Faith A et al. IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. Eur J Immunol 2000; 30:1683-90.
30. Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol 2006; 24:65-97.
31. Bonfield TL, Panuska JR, Konstan MW et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152:2111-8.
32. Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol 1997; 24:137-42; discussion 59-61.
33. Saadane A, Soltys J, Berger M. Role of IL-10 deficiency in excessive nuclear factor-kappaB activation and lung inflammation in cystic fibrosis transmembrane conductance regulator knockout mice. J Allergy Clin Immunol 2005; 115:405-11.
34. Chmiel JF, Konstan MW, Saadane A et al. Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice. Am J Respir Crit Care Med 2002; 165:1176-81.
35. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002; 13:357-68.
36. Nixon LS, Yung B, Bell SC et al. Circulating immunoreactive interleukin-6 in cystic fibrosis. Am J Respir Crit Care Med 1998; 157:1764-9.
37. Jones MM, Seilheimer DK, Pollack MS et al. Relationship of hyper-gammaglobulinemia, circulating immune complexes, and histocompatibility antigen profiles in patients with cystic fibrosis. Am Rev Respir Dis 1989; 140:1636-9.
38. Pedersen SS, Espersen F, Hoiby N et al. Immunoglobulin A and immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis. J Clin Microbiol 1990; 28:747-55.
39. Kobayashi H. Airway biofilms: implications for pathogenesis and therapy of respiratory tract infections. Treat Respir Med 2005; 4:241-53.
40. Greally P, Hussain MJ, Vergani D et al. Serum interleukin-1 alpha and soluble interleukin-2 receptor concentrations in cystic fibrosis. Arch Dis Child 1993; 68:785-7.
41. Hubeau C, Le Naour R, Abely M et al. Dysregulation of IL-2 and IL-8 production in circulating T lymphocytes from young cystic fibrosis patients. Clin Exp Immunol 2004; 135:528-34.
42. Kaisho T, Akira S. Dendritic-cell function in Toll-like receptor- and MyD88-knockout mice. Trends Immunol 2001; 22:78-83.
43. Park JY, Kim HY, Lee JY et al. Macrolide-affected Toll-like receptor 4 expression from Helicobacter pylori-infected monocytes does not modify interleukin-8 production. FEMS Immunol Med Microbiol 2005; 44:171-6.
44. Takizawa H. Airway inflammation and macrolides. Jpn J Antibiotics 1998; 52:46-9.